Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACERNASDAQ:HOTHOTCMKTS:IGXTNASDAQ:TORCNASDAQ:ZFGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACERAcer Therapeutics$0.66$0.74$0.55▼$4.56$16.15MN/AN/A574,675 shsHOTHHoth Therapeutics$1.21+0.4%$1.06$0.58▼$3.80$15.98M0.673.71 million shs132,991 shsIGXTIntelGenx Technologies$0.17$0.17$0.09▼$0.22$29.17M2.47N/AN/ATORCresTORbio$0.61-1.1%$12.16$0.86▼$10.50$22.13M2.431.15 million shs545,982 shsZFGNZafgen$3.20+2.9%$18.47$0.62▼$2.76$119.90M0.27360,199 shs516,014 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACERAcer Therapeutics0.00%0.00%0.00%0.00%0.00%HOTHHoth Therapeutics0.00%+6.64%-21.24%+43.47%+34.62%IGXTIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%TORCresTORbio-1.14%-9.48%-22.08%-9.54%-44.82%ZFGNZafgen+2.89%+3.90%+32.78%+63.27%-58.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACERAcer TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHOTHHoth Therapeutics1.5896 of 5 stars3.62.00.00.00.60.00.6IGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACERAcer Therapeutics 0.00N/AN/AN/AHOTHHoth Therapeutics 3.25Buy$4.00231.95% UpsideIGXTIntelGenx Technologies 0.00N/AN/AN/ATORCresTORbio 0.00N/AN/AN/AZFGNZafgen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HOTH, ZFGN, TORC, ACER, and IGXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.004/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACERAcer TherapeuticsN/AN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/AIGXTIntelGenx Technologies$1.04M28.05N/AN/A($0.07) per share-2.39TORCresTORbioN/AN/AN/AN/A$2.24 per shareN/AZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACERAcer Therapeutics-$26.24MN/A0.00∞N/AN/AN/AN/AN/AHOTHHoth Therapeutics-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)IGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/AN/AN/AN/AN/ATORCresTORbio-$82.74M-$2.41N/AN/AN/AN/A-78.12%-71.63%N/AZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/ALatest HOTH, ZFGN, TORC, ACER, and IGXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACERAcer TherapeuticsN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/ATORCresTORbioN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACERAcer TherapeuticsN/AN/AN/AHOTHHoth TherapeuticsN/A15.0915.08IGXTIntelGenx TechnologiesN/AN/AN/ATORCresTORbioN/A20.6920.69ZFGNZafgen0.266.566.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACERAcer TherapeuticsN/AHOTHHoth Therapeutics7.08%IGXTIntelGenx TechnologiesN/ATORCresTORbio46.19%ZFGNZafgen70.43%Insider OwnershipCompanyInsider OwnershipACERAcer Therapeutics20.20%HOTHHoth Therapeutics6.92%IGXTIntelGenx Technologies42.05%TORCresTORbio11.80%ZFGNZafgen14.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACERAcer Therapeutics3024.46 million19.52 millionNot OptionableHOTHHoth Therapeutics413.21 million12.30 millionNot OptionableIGXTIntelGenx Technologies38174.66 million101.21 millionNot OptionableTORCresTORbioN/A36.45 millionN/ANot OptionableZFGNZafgen3837.47 millionN/ANot OptionableHOTH, ZFGN, TORC, ACER, and IGXT HeadlinesRecent News About These CompaniesGSK/Sirtris compounds dogged by assay artifactsMay 21, 2024 | nature.comNTokyo Steel Manufacturing Co Ltd 5423May 16, 2024 | morningstar.comMDiagnosing Diabetes: Not So SimpleNovember 2, 2023 | medscape.comMDo New Weight Loss Meds Mean the End of Bariatric Surgery?October 6, 2023 | medscape.comMPrader-Willi syndromeAugust 23, 2023 | pharmaphorum.comPThe Omnipod 5 System: Trial Results From ENDO 2021August 4, 2023 | medscape.comMBeta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?July 5, 2023 | medscape.comMOral Semaglutide Brings GLP-1s to Primary CareMay 20, 2023 | medscape.comMClinical Trials - Different Phases of the trial News, Research and Latest UpdatesMay 20, 2023 | medindia.netMObesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital JournalMay 12, 2023 | news.google.comNWeight Loss and Obesity Management Market Insights With ... - Taiwan NewsMay 11, 2023 | news.google.comNGlobal Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern ExaminerMay 4, 2023 | news.google.comNWeight Loss and Obesity Management Market May See a Big Move ... - Digital JournalMay 2, 2023 | news.google.comNIronwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best StocksMay 2, 2023 | news.google.comNThe Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the CirculationApril 29, 2023 | medscape.comMFast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape ReferenceApril 21, 2023 | news.google.comNAnti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital JournalApril 20, 2023 | news.google.comNAnti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPRApril 14, 2023 | news.google.comNNew ADA Standards: Promoting HealthApril 13, 2023 | medscape.comMNew ADA Standards: Promoting HealthApril 13, 2023 | medscape.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOTH, ZFGN, TORC, ACER, and IGXT Company DescriptionsAcer Therapeutics NASDAQ:ACERAcer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.Hoth Therapeutics NASDAQ:HOTH$1.20 +0.01 (+0.42%) Closing price 07/3/2025 03:36 PM EasternExtended Trading$1.20 0.00 (0.00%) As of 07/3/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.IntelGenx Technologies OTCMKTS:IGXT$0.17 0.00 (0.00%) As of 05/27/2025IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.resTORbio NASDAQ:TORCAdicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.Zafgen NASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
